Gilead exercises option for Kymera's cancer drug candidate KT-200
Go back to Gilead exercises option for Kymera's cancer drug candidate KT-200| Gilead Sciences (NASDAQ: GILD) | Delayed: 124.58 +0.82 (0.66%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $123.76 | 52 Week High | $108.63 | |||
| Open | $124.30 | 52 Week Low | $71.39 | |||
| Day High | $124.59 | P/E | 68.83 | |||
| Day Low | $123.00 | EPS | $1.81 | |||
| Volume | 2,152,972 | |||||
| (NASDAQ: KYMR) | Delayed: 98.42 +7.99 (8.84%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $90.43 | 52 Week High | $ | |||
| Open | $92.84 | 52 Week Low | $ | |||
| Day High | $105.00 | P/E | N/A | |||
| Day Low | $91.74 | EPS | $ | |||
| Volume | 1,493,331 | |||||
